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Abstract
Background: Reducing substance use and unprotected sex by HIV-positive persons improves individual health status while
decreasing the risk of HIV transmission. Despite recommendations that health care providers screen and counsel their HIV-
positive patients for ongoing behavioral risks, it is unknown how to best provide ‘‘prevention with positives’’ in clinical
settings. Positive Choice, an interactive, patient-tailored computer program, was developed in the United States to improve
clinic-based assessment and counseling for risky behaviors.
Methodology and Findings: We conducted a parallel groups randomized controlled trial (December 2003–September
2006) at 5 San Francisco area outpatient HIV clinics. Eligible patients (HIV-positive English-speaking adults) completed an in-
depth computerized risk assessment. Participants reporting substance use or sexual risks (n=476) were randomized in
stratified blocks. The intervention group received tailored risk-reduction counseling from a ‘‘Video Doctor’’ via laptop
computer and a printed Educational Worksheet; providers received a Cueing Sheet on reported risks. Compared with
control, fewer intervention participants reported continuing illicit drug use (RR 0.81, 95% CI: 0.689, 0.957, p=0.014 at
3 months; and RR 0.65, 95% CI: 0.540, 0.785, p,0.001 at 6 months) and unprotected sex (RR 0.88, 95% CI: 0.773, 0.993,
p=0.039 at 3 months; and RR 0.80, 95% CI: 0.686, 0.941, p=0.007 at 6 months). Intervention participants reported fewer
mean days of ongoing illicit drug use (-4.0 days vs. -1.3 days, p=0.346, at 3 months; and -4.7 days vs. -0.7 days, p=0.130, at
6 months) than did controls, and had fewer casual sex partners at (22.3 vs. 21.4, p=0.461, at 3 months; and 22.7 vs. 20.6,
p=0.042, at 6 months).
Conclusions: The Positive Choice intervention achieved significant cessation of illicit drug use and unprotected sex at the
group-level, and modest individual-level reductions in days of ongoing drug use and number of casual sex partners
compared with the control group. Positive Choice, including Video Doctor counseling, is an efficacious and appropriate
adjunct to risk-reduction efforts in outpatient settings, and holds promise as a public health HIV intervention.
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Introduction
Advances in HIV treatment have dramatically increased patients’
duration and quality of life [1,2]. Because HIV-positive individuals
are living longer and may continue to engage in risky behaviors, new
prevention strategies now address the role of HIV-positive persons;
an approach called ‘‘prevention with positives.’’ To specifically
address prevention with HIV-positive individuals, the US Centers
for Disease Control (CDC) recommends that providers screen for
and intervene on transmission-related risk behaviors, monitor
behaviors that increase the risk of disease progression, and counsel
patients on how they can protect their own health [3].
Reducing or eliminating unprotected sex has traditionally been
a cornerstone of HIV prevention in the US [4]. In addition to the
risk of HIV transmission, unprotected sex may adversely affect the
HIV-positive individual’s health. New sexually transmitted
PLoS ONE | www.plosone.org 1 April 2008 | Volume 3 | Issue 4 | e1988infections may exacerbate discomfort, and can increase viral load
and accelerate disease progression [5,6].
Reducing substance use is another important strategy to reduce
transmissionandprotectthehealthofHIV-positiveindividuals[7,8].
Both illicit drug and excessive alcohol use are associated with high-
risk sexual behaviors [9–11]. Substance use is also a predictor of
incomplete adherence to antiretroviral therapy [6], which in turn
may lead to drug resistance [12,13], as well as to more rapid
progression to AIDS and mortality [14–16]. Consequently, reducing
sexual risk and substance use can be reframed as lifestyle changes
supporting the patient’s own health while avoiding conceptualizing
the HIV-infected person as a vector of disease [17].
Although the CDC recommends that providers screen and
counsel HIV-infected patients for ongoing behavioral risks [3],
many do not. Physicians’ risk-reduction efforts are frequently
constrained by discomfort with the topics, pessimism about
patients’ behavior change, confusion about their role as counselor,
lack of time, and lack of confidence in their skills [18–21].
Nevertheless, a growing body of evidence suggests that interven-
tions for HIV-positive individuals can reduce risky behaviors [22],
and brief motivational interventions decrease unprotected sex
[23], reduce harmful alcohol use [24], and increase adherence to
antiretroviral therapy [25].
Despite increasing interventions designed to reduce risky behav-
iors, few focus specifically on HIV-positive individuals [26], address
multiple risky behaviors [26,27], or target more than 1 vulnerable
population [27].A recent reviewof the literatureby Lyleset al.(2007)
found only 18 interventions that met the criteria for a best-evidence
HIV behavioral intervention as determined by the CDC’s HIV/
AIDS Prevention Research Synthesis Team. Of these, only 4
targeted HIV-positive individuals, with 1 exclusively for women and
1 exclusively for men who have sex with men. These interventions
alsodemanded substantial timecommitmentsfrom bothpatientsand
health care providers. Considering the existing constraints on
physicians’ risk screening and counseling practices [28], these
interventions are less than ideal for clinical practice settings.
Efficacious prevention interventions that can be seamlessly
integrated into HIV clinical settings are essential to address ongoing
sensitive risk behaviors. The Center for Health Improvement and
Prevention Studies (CHIPS) has adapted multimedia computer
technology to support these efforts, creating a computer program
that involves both patients and providers [29]. Delivered on laptop
computers in clinic settings, this computer program conducts in-
depth risk assessments, delivers tailored counseling messages, and
produces printed output for both the patient and provider. A novel
component is the ‘‘Video Doctor’’ intervention, an actor-portrayed
physician who engages patients in a confidential, ‘‘face-to-face’’
discussion about risky behavior. The Video Doctor simulates an
ideal conversation with a health care provider, and has been highly
acceptable to diverse primary care patients in the US [29].
Using a Video Doctor counselor and a framework that
emphasized concern for the patient’s own health rather than
solely transmission of HIV [17], we developed Positive Choice,a n
interactive computer program to improve screening and counsel-
ing about ongoing risky behaviors in HIV-infected patients. We
conducted a randomized, controlled trial of Positive Choice to test its
efficacy at reducing illicit drug use, risky alcohol drinking, and anal
or vaginal intercourse without a condom.
Methods
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1.
Sample size, sites, and recruitment
A series of power analyses were calculated for 2 group
comparisons of each risk as a binary outcome (any ongoing risk
vs. none) with at least 80% power to detect a difference in
proportions of at least 0.125 with the control group proportion in
the range 0.10 to 0.90 (2 tailed, a=0.05), resulting in a target
sample size of 526 participants.
Between December 2003 and September 2006 the Positive Choice
trial was integrated into 5 outpatient HIV clinics in the San
Francisco Bay Area, including 2 public hospitals, a community-
based organization, a private hospital, and a health maintenance
organization (HMO). Eligible participants were age 18 or older
and HIV-positive 3 months or longer. Positive Choice was available
in English only. Participants were recruited via clinic advertise-
ments (posters and flyers) and self-referred or were referred by
clinic staff or providers. Four sites allowed direct recruitment by
research assistants, who serially approached patients in waiting
rooms as they arrived for scheduled appointments. If patients
indicated an interest in participating, research assistants escorted
them to a private area of the clinic where eligibility criteria were
assessed in a structured in-person interview. All participants
provided informed consent and received a $40 gift card as
compensation for completing a baseline session. Compensation
increased to $50 and $60 at 3- and 6-month follow-ups. Retention
was maximized using frequent reminders by phone or mail. Study
procedures were approved by the University of California San
Francisco’s Committee on Human Research.
Risk assessment and randomization
Participants used a laptop computer to complete the Positive
Choice risk assessment, a low-literacy-demand computerized
interview with audio voiceover. Privacy was assured by use of a
private examination room and headphones. All baseline and
follow-up risk assessments were done approximately 1 hour prior
to a regularly scheduled medical appointment, allowing partici-
pants ample time to complete the computer session before the
scheduled medical appointment. In this way, Positive Choice was
integrated into the flow of each clinic.
The assessment collected self-reported demographic informa-
tion (including race/ethnicity), baseline clinical information (such
as length of time HIV-positive), and screened participants for
drug, alcohol, and sexual risks. The assessment captured days of
use in the past month for 10 illicit drugs. Drug risk was defined as
1) any use of the following: crack cocaine; methamphetamine;
powder cocaine; ‘‘speedball’’ (heroin with cocaine); or heroin; or 2)
3 or more days of use of the following: ‘‘downers’’ (e.g.,
barbiturates); non-prescribed opiates; inhalants; hallucinogens;
and ‘‘ecstasy’’ (methylenedioxymethamphetamine [MDMA]). To
avoid contradicting messages about purported medicinal use,
marijuana use was not categorized as a drug risk. Risky alcohol use
was defined as exceeding the US National Institute on Alcoholism
and Alcohol Abuse’s recommended number of drinks per week (14
or fewer for men; 7 or fewer for women) and/or 3 or more binge
drinking episodes (5 or more drinks on 1 occasion for men; 4 or
more drinks on 1 occasion for women) within the previous
3 months.
Sexual risk was defined as anal or vaginal intercourse without a
condom; the program did not inquire about oral sex. Participants
were asked for the total number of sex partners in the last
3 months, then asked to report condom use as a numeric
percentage, from 0% (never used) to 100% (consistently used),
with a main partner and/or up to 5 casual partners in the previous
3 months. Sexual risk was operationalized as a dichotomous
variable (100% condom use versus ,100%) with main and/or
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Participants were also asked about their sex partners’ HIV status
(HIV-negative, HIV-positive, or unknown) to allow further
tailoring of intervention messages; partners’ HIV status did not
determine sexual risk status.
Randomization by the computer occurred immediately upon
completion of the baseline risk assessment and was independent of
the research assistants. Participants reporting 1 or more risky
behaviors were stratified by risk profile (drug risk; alcohol risk; sex
risk; drug and alcohol risks; drug and sex risks; alcohol and sex
risks; drug, alcohol, and sex risks) then assigned to intervention or
control groups in blocks of 1, resulting in equivalent intervention
and control groups for each risk combination. Patients and their
providers were not informed of group assignment, although
assignment to the intervention group might have been deduced by
some patients and their providers by receipt of printed output
(Educational Worksheet and Cueing Sheet, respectively) from the
computer. Research assistants were aware of group assignment
only upon completion of the patient’s baseline session. Both
intervention and control participants completed follow-up risk
assessments 3 and 6 months post-baseline.
Video Doctor intervention
Upon completion of the risk assessment, the Positive Choice
program immediately played the Video Doctor clips for
participants randomized to the intervention group, thus creating
a seamless transition to the intervention segment. Interactive risk-
reduction messages, based on principles of Motivational Inter-
viewing [30,31], were delivered by an actor-portrayed Video
Doctor, whose tone was respectful and non-judgmental. These
messages simulated an ideal discussion where the health care
provider expressed reflexive understanding of the patient’s
concerns, showed compassion for the patient, and provided non-
judgmental counseling. We did not expect that a computer
program could replace a skilled counselor; but somewhat counter-
intuitively, computer technology may actually help increase fidelity
to some principles of Motivational Interviewing (MI). Correct
implementation of MI is highly dependent on an individual’s
counseling skills and abilities. By standardizing messages and using
complex, interactive programming to tailor responses, our
program was able to construct a seamless counseling session with
the Video Doctor closely adhering to several key principles of
Motivational Interviewing, including a patient-centered approach,
non-judgmental tone, empathy, support, and avoidance of
confrontation. The Video Doctor script and programming
avoided the inconsistencies, hesitation, or discomfort that occur
all too often in interpersonal encounters. Furthermore, our
program circumvented a common barrier to the wider application
of MI—the substantial time and training required by health care
providers to master it.
Using a library of digital video clips, extensive branching logic,
and participant input, the program tailored the video clips to the
participant’s gender, risk profile, and readiness to change. At the
conclusion of each session, the program printed 2 documents: 1)
an ‘‘Educational Worksheet’’ for participants with questions for
self-reflection, harm reduction tips, and local resources (Figure 1);
and 2) a ‘‘Cueing Sheet’’ for providers, which offered an at-a-
glance summary of the patient’s risk profile and readiness to
change, and suggested risk-reduction counseling statements
(Figure 2). The Cueing Sheet was discretely placed in the patient’s
medical record for the provider’s use during the medical
appointment. Providers were asked to check a box and sign the
Cueing Sheet to indicate whether a discussion took place.
Intervention participants received ‘‘booster’’ Video Doctor
counseling at 3 months, including feedback reflecting changes
made since baseline, and updated Cueing Sheets and Educational
Worksheets. Sample intervention components, including Video
Doctor clips, a Cueing Sheet, and an Educational Worksheet, are
available for review on our website, www.ucsf.edu/chips/(new)
research-poschoice.htm.
The control group did not interact with the Video Doctor and
did not receive the Educational Worksheets or the Cueing Sheets.
Following completion of the risk assessment they proceeded to
their medical appointment and received the clinic’s usual care.
Any risk assessment and counseling for the control group was
dependent on the medical providers’ own initiative and clinical
judgment and was not measured.
Statistical analysis
Baseline characteristics of the intervention and control groups
were compared, with p-values obtained by Fisher’s exact or chi-
square tests. Behavior change outcomes were examined using 3-
and 6-month follow-up data for participants reporting risky
behavior at baseline and were tabulated by group assignment as
binary outcomes (cessation vs. ongoing risky behavior) with
Fisher’s exact test p-values. Participants could report multiple
concurrent risky behaviors, but each outcome was analyzed
separately. A Bonferroni correction (a=0.05/3=0.0167) was used
to assess statistical significance among the 3 risks with 6-month
follow-up the primary time point. For all analyses, we assumed
that any participant enrolled in the study who failed to return for
follow-up continued their reported risky behavior, constituting a
worst-casesensitivityanalysis.Wealsoperformedalternateoutcomes
analyses with complete cases only, assuming participants lost to
follow-up were similar to those completing follow-ups. Pre-planned
sub-group analyses of outcomes were performed by participants’
gender, race/ethnicity, educational attainment, hepatitis C co-
infection, HIV viral load, source of HIV infection, previous
treatment for alcohol or drug abuse, main or casual sex partners,
and HIV status of sex partner(s). Univariate summary statistics of
mean changes and standard deviations were calculated for specific
behaviors in each risk among those completing follow-up. Measures
of change included number of drinks per week (for participants
drinking over the recommended limit), number of binge drinking
episodes, total days of all drug use, absolute percent change in self-
reported condom use with main and casual partners, and number of
casual sex partners.Differencesbetweengroupswerecompared with
t-test p-values. All analyses were done on SAS version 9.1 statistical
software (SAS Corporation, Cary NC, USA).
Results
Description of sample
We invited 971 patients to participate in Positive Choice; 19 (2%)
failed to meet eligibility criteria and 35 (4%) refused to participate.
The remaining 917 patients met eligibility criteria and completed
a baseline risk assessment (Figure 3). Of these, 476 participants
(52%) reported 1 or more risky behaviors and were stratified by
risk combination, then randomized. Five participants reported
illicit drug use as their only risk but not within the previous month;
we excluded these 5 participants, resulting in a sample of 471
participants for analysis. We achieved high retention for follow-
ups; 82% percent of the intervention group and 83% of the control
group completed 6-month sessions. Our sample was middle aged,
the majority male, and racially/ethnically diverse (Table 1). Most
participants had at least a high school diploma. There were no
significant differences in demographics or clinical variables
between intervention and control groups. There were more
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per week in the intervention group than control (51 vs. 37,
p=0.050).
Illicit drug use was reported by 200 participants (42% of sample
for analysis). Stimulants were the most frequently used drugs (crack
cocaine n=114; methamphetamine n=72). Risky drinking was
reported by 182 participants (39% of sample for analysis), the
majority of whom (n=168) were at risk for excessive binge
drinking episodes. Unprotected anal or vaginal intercourse was
reported by 284 participants (60% of sample for analysis), and
occurred most frequently with main partners only (n=126),
followed by casual partners only (n=95), and both main and
casual partners (n=63). These risky behaviors were not mutually
exclusive; 288 participants reported 1 risky behavior (61% of
sample for analysis), while 151 (32%) reported 2 risks, and 32 (7%)
reported all 3 risks.
Figure 1. Sample Positive Choice Educational Worksheet
doi:10.1371/journal.pone.0001988.g001
‘‘Video Doctor’’ Intervention
PLoS ONE | www.plosone.org 4 April 2008 | Volume 3 | Issue 4 | e1988Process measures
The average baseline risk assessment lasted 19 minutes for
participants without any risky behaviors, and 23 minutes for
intervention and control participants. The Video Doctor counseling
for intervention participants averaged 24 minutes in length across all
risk combinations. After the medical appointment and at the
conclusion of all study activities, research assistants administered a 4-
item acceptability interview to assess participants’ reactions to the
program. The majority of responses were positive: 892 (97%) ‘‘liked’’
the program or ‘‘liked [it] very much,’’ and 849 (93%) reported it was
easy to use. Only 118 (13%) stated the program was ‘‘too long,’’ and
only35(4%)reportedwantingmoreprivacywhenusingthecomputer.
Seventy-four percent (181/243) of baseline Cueing Sheets and
72% (131/182) of 3-month follow-up Cueing Sheets were checked
or signed by providers, indicating they were used in the medical
appointment. Researchers were unable to mandate that providers
Figure 2. Sample Positive Choice Cueing Sheet
doi:10.1371/journal.pone.0001988.g002
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doi:10.1371/journal.pone.0001988.g003
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Sheets, they often reported deferring their use because of medical
contingencies in the appointment.
Behavior change outcomes
We compared binary outcomes (cessation vs. any ongoing risky
behavior) for illicit drug use, risky drinking, and unprotected anal
or vaginal sex among intervention and control participants who
reported the corresponding risk at baseline. We report proportions
of continued drug, alcohol, and sexual risk behaviors in Table 2.
Our assumption that participants lost to follow-up continued the
risky behavior yielded a conservative estimate of intervention
effects; we also present alternate outcomes where those lost to
follow-up were excluded; censoring participants lost to follow-up
did not substantively change outcomes. We report mean changes
and standard deviations for specific risky behaviors among only
those completing follow-ups in Table 3.
Illicit drug use. The intervention group was significantly less
likely than the control group to report any ongoing drug use at
3 months (67% vs. 82%, RR 0.81, 95% CI: 0.689, 0.957,
p=0.014). At 6 months, even fewer intervention participants
continued any drug use compared with control (56% vs. 86%, RR
0.65, 95% CI: 0.540, 0.785, p,0.001). Univariate measures of
change at 3-month follow-up showed that total days of any drug
use in the previous month was reduced by a mean of 4.0 days (SD
11.8 days) in the intervention group and 1.3 days (SD 21.2 days)
in control (p=0.346). At 6 months, the intervention group’s mean
reduction of any drug use was 4.7 days (SD 11.6 days) compared
with the control group’s mean reduction of 0.7 days (SD
19.7 days) (p=0.130).
Risky drinking. At 3- and 6-month follow-ups, both
intervention and control groups showed no significant
Table 1. Demographic and clinical characteristics of Positive
Choice sample included in analysis
Variable
Intervention
(n=240)
Control
(n=231) P-value
Age, mean (SD), y 43.9 ( 9.2 ) 44.3 ( 9.0 ) 0.604
Gender, n (%)
Female 56 (23) 45 (19) 0.315
Male 184 (77) 186 (81)
Race/Ethnicity, n (%)
Hispanic/Latino 39 (16) 20 (9) 0.088
Black or African-American 118 (49) 118 (51)
White 65 (27) 72 (31)
Other or multiple races 18 (8) 21 (9)
Educational Attainment, n (%)
Less than high school diploma 47 (20) 38 (16) 0.470
High school diploma or GED 139 (58) 127 (55)
College degree 34 (14) 42 (18)
Graduate or professional degree 20 (8) 24 (10)
Transmission category, n (%)
MSM or MSM/W * 122 (51) 119 (51) 0.588
Other sexual risk 55 (23) 46 (20)
Injecting drug use alone 19 (8) 25 (11)
Injecting drug use & other risk(s) 13 (5) 19 (8)
Blood transfusion or blood products 5 (2) 2 (1)
Multiple Risks 9 (4) 6 (3)
Don’t Know or other 17 (7) 14 (6)
HIV Viral Load, n (%)
Undetectable 111 (46) 102 (44) 0.716
#10,000 copies 45 (19) 55 (24)
10,001–50,000 copies 27 (11) 25 (11)
.50,000 copies 14 (6) 14 (6)
Don’t know 43 (18) 35 (15)
Hepatitis-C Co-Infection, n (%)
No 174 (72) 147 (64) 0.103
Yes 46 (19) 62 (27)
Don’t know 20 (8) 22 (9)
Risky behavior,** n (%)
Any drug use 105 (44) 95 (41) 0.565
Crack cocaine use 60 (25) 54 (23) 0.681
Methamphetamine use 31 (13) 41 (18) 0.145
Any risky drinking 92 (38) 90 (39) 0.89
Over the recommended limit 51 (21) 37 (16) 0.050
$3 binge drinking episodes 84 (35) 84 (36) 0.757
Any unprotected sex 143 (60) 141 (61) 0.747
With main partner 99 (41) 90 (39) 0.612
With casual partner(s) 74 (31) 84 (36) 0.204
*Men who have sex with men (MSM), or men who have sex with men and women
(MSM/W)
**Not mutually exclusive; participants could report multiple risky behaviors
doi:10.1371/journal.pone.0001988.t001
Table 2. Ongoing risky behavior at 3 and 6 months among
Positive Choice participants reporting the behavior at baseline
Worst-case sensitivity analysis (assumes ongoing risk for those lost to
follow-up)
Risky Behavior Intervention Control Relative Risk P-value
n/N (%) n/N (%) (95% CI)
Any drug use
3 months 70/105 (67) 78/95 (82) 0.81 (0.689, 0.957) 0.014*
6 months 59/105 (56) 82/95 (86) 0.65 (0.540, 0.785) ,0.001*
Any risky drinking
3 months 48/92 (52) 56/90 (62) 0.84 (0.651, 1.080) 0.172
6 months 47/92 (51) 53/90 (59) 0.87 (0.666, 1.130) 0.291
Any unprotected sex
3 months 104/143 (73) 117/141 (83) 0.88 (0.773, 0.993) 0.039
6 months 88/143 (62) 108/141 (77) 0.80 (0.686, 0.941) 0.007*
Alternate analysis (excludes participants lost to follow-up)
Any drug use
3 months 47/82 (57) 50/67 (75) 0.77 (0.608, 0.970) 0.029
6 months 39/85 (46) 60/73 (82) 0.56 (0.433, 0.720) ,0.001*
Any risky drinking
3 months 36/80 (45) 36/70 (51) 0.88 (0.628, 1.220) 0.432
6 months 34/79 (43) 38/75 (51) 0.85 (0.606, 1.191) 0.343
Any unprotected sex
3 months 61/103 (62) 91/115 (79) 0.79 (0.657, 0.938) 0.006*
6 months 67/122 (55) 85/118 (72) 0.76 (0.627, 0.928) 0.006*
*Significant with Bonferroni correction (a=0.05/3=0.0167)
doi:10.1371/journal.pone.0001988.t002
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95% CI: 0.651, 1.080, p=0.172 at 3 months; and 51% vs. 59%,
RR 0.87, 95% CI: 0.666, 1.130, p=0.291 at 6 months). Looking
at univariate measures of change, both groups showed similar
reductions of binge drinking episodes and number of drinks per
week (for participants drinking over the recommended limit) at
both follow-ups.
Sexual risks. At 3 months, both intervention and control
groups reported less ongoing unprotected anal or vaginal
intercourse (73% vs. 83%, RR 0.88, 95% CI: 0.773, 0.993,
p=0.039), however the result did not meet the level of significance
set by the Bonferroni correction (p,0.0167). At 6 months, we
found a statistically significant reduction of ongoing unprotected
sex in the intervention group compared with control (62% vs.
77%, RR 0.80, 95% CI: 0.686, 0.941, p=0.007). Condom use
with main and casual partners was increased by similar modest
proportions in both intervention and control groups at both
follow-ups. The intervention group showed greater reductions in
mean number of casual sex partners at 3 and 6 months compared
to control (22.3 vs. 21.4, p=0.461, at 3 months; and 22.7 vs.
20.6, p=0.042, at 6 months).
Sub-group analyses. Preplanned sub-group analyses by
participants’ gender, race/ethnicity, hepatitis-C co-infection,
HIV viral load, source of HIV infection, or sex partners’ HIV
status did not differ from aggregate results. Interestingly,
participants’ previous treatment for alcohol or drug abuse did
not affect substance use outcomes.
Adverse events. Because of the sensitive and potentially
stigmatizing nature of substance use and sexual behavior, the study
team instituted a Data Safety and Monitoring Plan for adverse
events, specifically for breach of confidentiality and participants’
emotional distress. There were 2 incidents of perceived breaches of
confidentiality resulting from participants who did not recall that
providers would be given the Cueing Sheet stating their self-
reported risky behaviors; both incidents were successfully resolved
and the 2 participants continued in the study. Five study
participants died during the data collection period. Investigations
found that all deaths were attributable to HIV disease and were
not associated with participation in the trial.
Discussion
The Positive Choice program identified a high prevalence of
ongoing risky behaviors among HIV-positive adults in medical
care and achieved significant cessation of illicit drug use and
unprotected sex at the group-level, and modest individual-level
reductions in days of ongoing drug use and number of casual sex
partners compared to the control group. The large trial sample
included several important US sub-groups—African-Americans
(50% of sample), men who have sex with men (51%), and women
(21%)—that are representative of urban, HIV-positive adults in
care in the US. Losses to follow-up were low and balanced by
randomization group.
Positive Choice may be an important adjunct to risk-reduction
efforts in routine clinical practice. It incorporates or exceeds all
criteria for a best-evidence HIV behavioral intervention as
determined by the CDC’s HIV/AIDS Prevention Research
Synthesis Team, such as prospective design, random assignment
to study arms, at least 3 months of follow-up, and at least 70%
retention for follow-up [32]. Positive Choice extends previous efforts
since behavioral interventions for HIV prevention have tradition-
ally focused on sexual behaviors. A review of the recent literature
(2000–2004) found only 3 out of 18 (17%) best-evidence
behavioral interventions attempted to reduce drug use, either
alone or combined with sexual risks [27]. Drug and alcohol use are
associated with increased risky sexual behaviors and present
additional barriers to optimal medical care, reinforcing the need
for integrated risk-reduction strategies. Positive Choice addresses
multiple risky behaviors and frames these behaviors as a hazard to
the patient’s own health, in addition to HIV transmission. Positive
Choice also illustrates a key public health principle—that modest
changes at the individual level may actually achieve significant
effects at the group level. An additional advantage of Positive Choice
is its brevity, requiring less than an hour of patients’ time for each
session before the medical appointment and no continuing medical
education for providers given the ease of use of the Cueing Sheets.
HIV care providers’ usual screening for and counseling about
risky behaviors may be impeded by concerns about stigmatizing
the patient, jeopardizing trust between patient and provider, or
ethical issues, such as the ‘‘duty to warn’’ HIV-negative sex
partners [17]. It is not surprising that a recent survey found overall
low rates of transmission prevention counseling to both newly
diagnosed and established HIV-positive patients [28]. The Positive
Choice program successfully overcame providers’ traditional
barriers to consistent risk screening and counseling by conducting
the risk assessment and delivering tailored risk-reduction counsel-
ing prior to the medical appointment. Because health risk
information was shared with the provider in real time via the
Cueing Sheet, the program supported the patient-provider
relationship for improved disease management and risk-reduction
counseling. An intervention that focused solely on the threat of
HIV transmission would have likely brought up patient and
provider resistance. By framing risky behaviors as a concern for
the patient’s own health as well as transmission to others, Positive
Choice reduced potential stigma and avoided conceptualizing the
individual simply as a vector of disease.
Table 3. Summary measures of change at 3 and 6 months
among Positive Choice participants completing a follow-up
session *
Measure of
behavior change N Mean (SD) N Mean (SD) P-value
Days of drug use in past 30 days
3 months 82 24.0 (11.8) 67 21.3 (21.2) 0.346
6 months 85 24.7 (11.6) 73 20.7 (19.7) 0.130
Binge drinking episodes in past 3 months
3 months 72 24.2 (7.0) 66 22.9 (7.3) 0.265
6 months 71 23.6 (14.5) 69 23.8 (11.1) 0.899
Number of drinks per week
3 months 43 29.7 (12.6) 25 28.1 (18.7) 0.703
6 months 45 212.7 (13.6) 31 213.7 (14.9) 0.750
Absolute percent change in condom use with main partners
3 months 75 +0.3 (0.5) 73 +0.2 (0.4) 0.327
6 months 84 +0.4 (0.5) 77 +0.2 (0.5) 0.091
Absolute percent change in condom use with casual partners
3 months 53 +0.3 (0.5) 66 +0.3 (0.5) 0.707
6 months 63 +0.3 (0.5) 68 +0.3 (0.5) 0.858
Number of casual sex partners
3 months 78 22.3 (9.2) 88 21.4 (7.9) 0.461
6 months 89 22.7 (8.4) 93 20.6 (5.6) 0.042
*Excludes participants lost to follow-up
doi:10.1371/journal.pone.0001988.t003
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diverse, English-speaking populations in the US. We make no
claims, however, about other settings. Given the worldwide HIV
epidemic, future research should explore the efficacy of Positive
Choice in other languages, sociocultural contexts, or populations.
While our findings are limited to risk reduction in HIV-positive
individuals, similar strategies may be effective at promoting
behavior change in populations at risk for HIV, as well as
assessing and counseling persons suffering from other chronic
conditions such as diabetes or hypertension, and their underlying
risk factors, such as nutrition, physical activity, and smoking.
We recognize several possible limitations. First, there may have
been differential disclosure of sensitive behaviors. This bias may
have been further enhanced by the possible reporting of risky
behaviors to providers through Cueing Sheets. We are unable to
validate participants’ self-reports, but remain convinced that
computerized questionnaires yield more disclosure of sensitive
topics than do other, traditional methods, such as face-to-face
interviews or paper questionnaires [33,34]. Although our previous
research found that sharing risk information with providers did not
inhibit patients’ disclosure of sensitive behaviors [33], we have no
evidence to deny this occurring in the present study. Second, our
risk assessment questions did not assess contextual sexual risk-
reduction strategies, such as serosorting (seeking sex only with
other HIV-positive people) or strategic positioning (adopting a
receptive role with HIV-negative or unknown status partners)
[35,36]. Our trial emphasized outcomes that are reframed as
potential acquisition risks to the participant (e.g. new sexually
transmitted infections) rather than HIV transmission risks to
partners. Future studies may explore these contextual aspects of
partner selection and related sexual risk-reduction strategies.
Third, we failed to find a significant intervention effect for alcohol
risk and speculate that risky drinking might differ from other risky
behaviors. Given equivalent reductions by the control group, risky
drinking may be particularly responsive to repeated self-assess-
ments. Alternatively, our intervention might have been too brief or
the Positive Choice Video Doctor model might not be well suited to
address risky drinking. Further complicating the topic, alcohol use
is legal, socially sanctioned, and may be consumed appropriately.
Perhaps risky drinking is more difficult to define than other risks.
We recommend that future studies explore differential interven-
tion effects by type of risk. Fourth, absolute risk behavior declined
over time among all participants. For example, the proportion of
each control group reporting cessation of risk ranged from 14% for
any drug use at 6 months (1-[82/95]=0.137) to 41% for any risky
drinking at 6 months (1-[53/90]=0.411). These declines are
consistent with results from other randomized controlled trials of
behavioral interventions with HIV-positive individuals [37,38] and
may be explained by the Hawthorne effect, i.e., participants
reported declines because they knew they were being studied.
Alternatively, declines may have resulted from regression toward
the mean, i.e., participants exceeding risk thresholds at enrollment
were above their individual averages and fell back to or below
their averages at follow-up. The Hawthorne effect in particular is
well known in HIV prevention research [39,40]. This phenom-
enon, considered a by-product of repeated self-assessments of
behavior, is disparately regarded as a major challenge to internal
validity [41] or as a potential intervention in itself [42]. Our
findings illustrate the complexities inherent in understanding and
changing human behaviors. Finally, the discrete contribution of
each of the 3 intervention components—Video Doctor counseling,
patient Educational Worksheet, or provider Cueing Sheet—
remains unknown and worthy of future study.
Responding to calls for ‘‘prevention with positives’’ interven-
tions, the Positive Choice program was designed to support medical
providers’ risk-reduction efforts with minimal additional burden.
Positive Choice’s Video Doctor counseling, patient Educational
Worksheet, and provider Cueing Sheet achieved important
reductions in risky behaviors among HIV-positive persons. Given
the challenges of changing human behavior, our results are
notable. Positive Choice is an efficacious adjunct to routine medical
care for HIV-positive patients with the capacity to have important
clinical and public health impact.
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